The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcγ Receptors on Macrophages
Abstract
Trastuzumab has been used for the treatment of HER2-overexpressing breast cancer for more than a decade, but the mechanisms of action for the therapy are still being actively investigated. Ab-dependent cell-mediated cytotoxicity mediated by NK cells is well recognized as one of the key mechanisms of action for trastuzumab, but trastuzumab-mediated Ab-dependent cellular phagocytosis (ADCP) has not been established. In this study, we demonstrate that macrophages, by way of phagocytic engulfment, can mediate ADCP and cancer cell killing in the presence of trastuzumab. Increased infiltration of macrophages in the tumor tissue was associated with enhanced efficacy of trastuzumab whereas depletion of macrophages resulted in reduced antitumor efficacy in mouse xenograft tumor models. Among the four mouse FcγRs, FcγRIV exhibits the strongest binding affinity to trastuzumab. Knockdown of FcγRIV in mouse macrophages reduced cancer cell killing and ADCP activity triggered by trastuzumab. Consistently, an upregulation of FcγRIV expression by IFN-γ triggered an increased ADCP activity by trastuzumab. In an analogous fashion, IFN-γ priming of human macrophages increased the expression of FcγRIII, the ortholog of murine FcγRIV, and increased trastuzumab-mediated cancer cell killing. Thus, in two independent systems, the results indicated that activation of macrophages in combination with trastuzumab can serve as a therapeutic strategy for treating high HER2 breast cancer by boosting ADCP killing of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2-targeting mAbs also elicit antibody-dependent cellular phagocytosis (ADCP), involving the clearance of antibodybound tumor cells by macrophages (Shi et al., 2015), a phenomenon that may be accompanied by macrophage polarization towardanM2-like immunosuppressive phenotype (Su et al., 2018).”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Shi et al., 2015
In the citing paper
“induction of ADCP of HER2-expressing cancer cells”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Shi et al., 2015
Citations
Cites
2 retracted
She, Q.-B., Chandarlapaty, S., Ye, Q., Lobo, J., Haskell, K. M., Leander, K. R., DeFeo-Jones, D., Huber, H. E., & Rosen, N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 301 · cited 1×
“Other mechanisms of action of trastuzumab, including downregulation of HER2 expression (6) and inhibition of HER2 oncogenic signaling (2, 4), might also be involved.”
BackgroundRetractedKohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226 · cited 1×
“Therefore, antitumor efficacy of trastuzumab in the mouse group with macrophage depletion by clodrosome might be contributed by an NK cell– mediated ADCC effect, as ADCC as a mechanism of action for trastuzumab was reported previously (27, 29).”
BackgroundRetractedInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“Studies have shown that mice with Fcg-chain knockout (g) or knockout of individual activating FcgRs lost immune effector functions of Abs and resulted in reduced antitumor efficacy of trastuzumab (22, 32, 33).”
BackgroundNagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“Other mechanisms of action of trastuzumab, including downregulation of HER2 expression (6) and inhibition of HER2 oncogenic signaling (2, 4), might also be involved.”
BackgroundDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037 · cited 1×
“It has been shown that FcgRIV is important in mediating the function of anticancer Ab (IgG2a) in the model of lung and liver metastases using murine melanoma cells, and in an anti-CD20 Abdependent B cell depletion model (24, 36, 37).”
BackgroundMusolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“Clinical studies have implicated the important role of FcgRIII in trastuzumab efficacy (38), even though function of FcgRIII on NK cells is considered mainly to contribute to cancer cell killing through ADCC (39).”
BackgroundBone Marrow-Derived Macrophages (BMM): Isolation and Applications
Weischenfeldt, J., & Porse, B. (2008) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot5080 · Cited by 955 · cited 2×
“Briefly, the isolated bone marrow cells were cultured in complete RPMI 1640 medium supplemented with 10% FCS and 30% pretested conditioned medium from the L929 cell line as a source of M-CSF for 5 d (17).”
BackgroundMethodEngineered antibody Fc variants with enhanced effector function
Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., Chan, C., Chung, H. S., Eivazi, A., Yoder, S. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508123103 · Cited by 803 · cited 1×
“In this study, we demonstrated that activated macrophages readily phagocytosed trastuzumab-coated cancer cells (ADCP) and mediated Ab-dependent cancer cell killing in coculture conditions in vitro, and the results are consistent with the study reported previously (16).”
ResultFcγRIV: A Novel FcR with Distinct IgG Subclass Specificity
Nimmerjahn, F., Bruhns, P., Horiuchi, K., & Ravetch, J. V. (2005) · Immunity · doi:10.1016/j.immuni.2005.05.010 · Cited by 660 · cited 4×
“FcgRIV binds to mouse IgG2a and IgG2b with intermediate affinity, but it has no detectable binding to mouse IgG1 or IgG3 (22).”
BackgroundInfluentialThe function of Fcγ receptors in dendritic cells and macrophages
Guilliams, M., Bruhns, P., Saeys, Y., Hammad, H., & Lambrecht, B. N. (2014) · Nature Reviews Immunology · doi:10.1038/nri3582 · Cited by 639
Roles of Fc receptors in autoimmunity
Takai, T. (2002) · Nature Reviews Immunology · doi:10.1038/nri856 · Cited by 626 · cited 2×
“Human immune cells have a corresponding family of FcgRs, including FcgRI (CD64), FcgRIIA (CD32A), FcgRIIB (CD32B), and FcgRIII (CD16A/B) (35).”
BackgroundArnould, L., Gelly, M., Penault-Llorca, F., Benoit, L., Bonnetain, F., Migeon, C., Cabaret, V, Fermeaux, V, Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 545 · cited 10×
“Studies have shown that higher affinity interactions between Ab and FcgRs promote more robust ADCC and ADCP activities and are associated with better therapeutic efficacy of the anti-CD20 Ab rituximab (24, 25).”
BackgroundInfluentialFc RECEPTORS AND THEIR INTERACTIONS WITH IMMUNOGLOBULINS
Raghavan, M., & Bjorkman, P. J. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.181 · Cited by 314 · cited 1×
“IgG Abs interact with a family of FcgRs on immune cells and trigger immune effector functions such as ADCC and ADCP against infectious or pathological cells such as cancer cells (30, 31).”
BackgroundOptimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
Richards, J. O., Karki, S., Lazar, G. A., Chen, H., Dang, W., & Desjarlais, J. R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0201 · Cited by 313 · cited 9×
“Studies have shown that higher affinity interactions between Ab and FcgRs promote more robust ADCC and ADCP activities and are associated with better therapeutic efficacy of the anti-CD20 Ab rituximab (24, 25).”
BackgroundInfluentialLeidi, M., Gotti, E., Bologna, L., Miranda, E., Rimoldi, M., Sica, A., Roncalli, M., Palumbo, G. A., Introna, M., & Golay, J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0713732 · Cited by 272 · cited 1×
“diated by activated macrophages can kill tumor cells (14).”
BackgroundTrastuzumab-Induced HER Reprogramming in “Resistant” Breast Carcinoma Cells
Narayan, M., Wilken, J. A., Harris, L. N., Baron, A. T., Kimbler, K. D., & Maihle, N. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1056 · Cited by 240
Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F., & Tedder, T. F. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052283 · Cited by 237 · cited 2×
“Studies have shown that higher affinity interactions between Ab and FcgRs promote more robust ADCC and ADCP activities and are associated with better therapeutic efficacy of the anti-CD20 Ab rituximab (24, 25).”
BackgroundMinard-Colin, V., Xiu, Y., Poe, J. C., Horikawa, M., Magro, C. M., Hamaguchi, Y., Haas, K. M., & Tedder, T. F. (2008) · Blood · doi:10.1182/blood-2008-01-135160 · Cited by 218
Cooley, S., Burns, L. J., Repka, T., & Miller, J. S. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00089-2 · Cited by 213
Taskinen, M., Karjalainen-Lindsberg, M.-L., Nyman, H., Eerola, L.-M., & Leppä, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0778 · Cited by 212 · cited 1×
“patients undergoing rituximab treatment (9).”
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
Nimmerjahn, F., Lux, A., Albert, H., Woigk, M., Lehmann, C., Dudziak, D., Smith, P., & Ravetch, J. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014515107 · Cited by 200 · cited 1×
“FcgRIV is a newer member of the family and maps in the 75-kb genomic interval between FcgRII and FcgRIII; its expression is restricted to myeloid lineage cells (34).”
BackgroundPetricevic, B., Laengle, J., Singer, J., Sachet, M., Fazekas, J., Steger, G., Bartsch, R., Jensen-Jarolim, E., & Bergmann, M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-307 · Cited by 192
Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
Beano, A., Signorino, E., Evangelista, A., Brusa, D., Mistrangelo, M., Polimeni, M. A., Spadi, R., Donadio, M., Ciuffreda, L., & Matera, L. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-25 · Cited by 178
Carson, W. E., Parihar, R., Lindemann, M. J., Personeni, N., Dierksheide, J. E., Meropol, N. J., Baselga, J. M., & Caligiuri, M. A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<3016::aid-immu3016>3.0.co;2-j · Cited by 175
Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions In Vivo
Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M., Dudziak, D., & Nimmerjahn, F. (2011) · Immunity · doi:10.1016/j.immuni.2011.11.009 · Cited by 152 · cited 1×
“Studies have shown that mice with Fcg-chain knockout (g) or knockout of individual activating FcgRs lost immune effector functions of Abs and resulted in reduced antitumor efficacy of trastuzumab (22, 32, 33).”
BackgroundTumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function
Grugan, K. D., McCabe, F. L., Kinder, M., Greenplate, A. R., Harman, B. C., Ekert, J. E., van Rooijen, N., Anderson, G. M., Nemeth, J. A., Strohl, W. R., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201889 · Cited by 126 · cited 1×
“the promotion of tumor progression and metastasis (7, 8).”
BackgroundSelf-citationMacrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Oflazoglu, E., Stone, I. J., Gordon, K. A., Grewal, I. S., van Rooijen, N., Law, C., & Gerber, H. (2007) · Blood · doi:10.1182/blood-2007-06-097014 · Cited by 117 · cited 1×
“anti-CD30 (11), and anti-CD40 (12) mAbs in preclinical studies.”
BackgroundGlycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study
Zhang, N., Liu, L., Dumitru, C. D., Houston-Cummings, N. R., Cukan, M. C., Jiang, Y., Li, Y., Li, F., Mitchell, T., Mallem, M. R., et al. (2011) · mAbs · doi:10.4161/mabs.3.3.15532 · Cited by 97 · cited 1×
“Binding constant (Kd) of trastuzumab to human FcgRIII in comparison with murine FcgRIV was determined using the surface plasmon resonance method with a Biacore T-100 instrument as we described previously (20).”
MethodSelf-citationLoisel, S., Ohresser, M. C. P., Pallardy, M. J., Daydé, D., Berthou, C., Cartron, G., & Watier, H. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.11.010 · Cited by 93 · cited 1×
“Multiple FcgRs (FcgRI, II, III, and IV) are expressed on murine macrophages (21).”
BackgroundRole of Fcγ receptors in cancer and infectious disease
Wallace, P. K., Howell, A. L., & Fanger, M. W. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.6.816 · Cited by 90
Otten, M. A., van der Bij, G. J., Verbeek, S. J., Nimmerjahn, F., Ravetch, J. V., Beelen, R. H. J., van de Winkel, J. G. J., & van Egmond, M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6829 · Cited by 89 · cited 1×
“It has been shown that FcgRIV is important in mediating the function of anticancer Ab (IgG2a) in the model of lung and liver metastases using murine melanoma cells, and in an anti-CD20 Abdependent B cell depletion model (24, 36, 37).”
BackgroundOflazoglu, E., Stone, I. J., Brown, L. L., Gordon, K. A., van Rooijen, N., Jonas, M., Law, C.-L., Grewal, I. S., & Gerber, H.-P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604812 · Cited by 81 · cited 1×
“anti-CD30 (11), and anti-CD40 (12) mAbs in preclinical studies.”
BackgroundWolterink, S., Moldenhauer, G., Fogel, M., Kiefel, H., Pfeifer, M., Lüttgau, S., Gouveia, R. M., Costa, J., Endell, J., Moebius, U., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3730 · Cited by 73 · cited 1×
“administration of 200 ml clodrosome (5 mg/ml; Encapsula NanoSciences, Brentwood, TN) weekly as reported (19).”
BackgroundIdentification of CD16-2, a novel mouse receptor homologous to CD16/FcγRIII
Mechetina, L. V., Najakshin, A. M., Alabyev, B., Chikaev, N. A., & Taranin, A. V. (2002) · Immunogenetics · doi:10.1007/s00251-002-0486-0 · Cited by 72 · cited 2×
“Human FcgRIII (CD16) shares 60% similarity in amino acid sequence with mouse FcgRIV/CD16-2 (22, 23).”
BackgroundFan, X., Brezski, R. J., Fa, M., Deng, H., Greenplate, A. R., Gonzalez, A. O., Dubinsky, W. P., Strohl, W. R., Jordan, R. E., Zhang, N., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3240 · Cited by 63 · cited 2×
“Binding of mouse FcgRs with trastuzumab was also determined by ELISA adapted from a reported method (18), and FcgR proteins were from Invitrogen.”
MethodSelf-citationShi, Y., Fan, X., Meng, W., Deng, H., Zhang, N., & An, Z. (2014) · Breast Cancer Research · doi:10.1186/bcr3637 · Cited by 61 · cited 2×
“Our group demonstrated recently that engagement of immune cells that express FcgRs with trastuzumab-coated cancer cells mediated HER2 downregulation in the target cells (6).”
BackgroundSelf-citationTai, Y., Horton, H. M., Kong, S., Pong, E., Chen, H., Čemerski, S., Bernett, M. J., Nguyen, D.-H. T., Karki, S., Chu, S. Y., et al. (2012) · Blood · doi:10.1182/blood-2011-06-364521 · Cited by 45 · cited 1×
“Studies have shown that higher affinity interactions between Ab and FcgRs promote more robust ADCC and ADCP activities and are associated with better therapeutic efficacy of the anti-CD20 Ab rituximab (24, 25).”
BackgroundLin, Z.-X., Bai, B., Cai, Q.-C., Cai, Q.-Q., Wang, X., Wu, X.-Y., & Huang, H.-Q. (2012) · Medical Oncology · doi:10.1007/s12032-012-0244-6 · Cited by 28 · cited 1×
“the promotion of tumor progression and metastasis (7, 8).”
BackgroundFcγ receptors in cancer and infectious disease
Fanger, M. W., & Erbe, D. V. (1992) · Immunologic Research · doi:10.1007/bf02919127 · Cited by 13
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Tumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
“In addition, trastuzumab, a monoclonal antibody drug used for the therapy of HER2-overexpressing breast cancer, has been found to trigger macrophage-mediated phagocytic killing of cancer cells in vitro and in vivo [96].”
BackgroundProgress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
“Clinically approved anti-cancer monoclonal antibodies such as rituximab and trastuzumab have been demonstrated to exert their therapeutic effects, primarily or in part, through macrophage-mediated ADCP [90][91].”
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Stanton, S. E., & Disis, M. L. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0165-6 · Cited by 828
Targeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Metadata
- Authors
- Shi, Y., Fan, X., Deng, H., Brezski, R. J., Rycyzyn, M., Jordan, R. E., Strohl, W. R., Zou, Q., Zhang, N., & An, Z.
- Affiliations
- Army Medical University (CN)
- Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
- Janssen Research & Development (United States) (US)
- Corresponding author
- Shi, Yun
- Fan, Xuejun
- Deng, Hui
- Zhang, Ningyan
- An, Zhiqiang
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-01
- Volume
- 194
- Issue
- 9
- Pages
- 4379-4386
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1589766395
- Cited by
- 195
- References
- 40
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 22 · 2023: 19 · 2022: 27 · 2021: 23 · 2020: 20 · 2019: 16 · 2018: 13 · 2017: 19 · 2016: 6 · 2015: 3
- FWCI
- 11.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- trastuzumab, HER2-positive breast cancer, antibody-dependent cellular phagocytosis, macrophages, Fc gamma receptor, FcγRIV, FcγRIII, interferon-gamma, macrophage activation, tumor-associated macrophages, phagocytic killing, antitumor immunity
- MeSH terms
- Trastuzumab, Animals, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Agents, Cytotoxicity, Immunologic, Disease Models, Animal, Humans, Macrophages, Neoplasms, Phagocytosis, Gene Expression, Receptors, IgG, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Cell Line, Tumor, Mice, Antibodies, Monoclonal, Humanized, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.